vs
Healthpeak Properties（DOC）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Healthpeak Properties的季度营收约是Royalty Pharma plc的1.2倍（$719.4M vs $622.0M），Healthpeak Properties净利率更高（73.2% vs 34.4%，领先38.7%），Royalty Pharma plc同比增速更快（4.8% vs 3.1%），过去两年Healthpeak Properties的营收复合增速更高（8.9% vs 4.6%）
Healthpeak Properties是美国医疗地产领域的房地产投资信托基金，核心投资范畴覆盖老年住宅、生命科学相关物业及医疗办公楼三类资产。公司2007年于马里兰州组建，总部设在科罗拉多州丹佛市，在尔湾、纳什维尔、旧金山均设有办事处，截至2019年12月31日共持有617处物业的权益。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
DOC vs RPRX — 直观对比
营收规模更大
DOC
是对方的1.2倍
$622.0M
营收增速更快
RPRX
高出1.7%
3.1%
净利率更高
DOC
高出38.7%
34.4%
两年增速更快
DOC
近两年复合增速
4.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $719.4M | $622.0M |
| 净利润 | $114.0M | $214.2M |
| 毛利率 | — | — |
| 营业利润率 | 17.4% | 62.4% |
| 净利率 | 73.2% | 34.4% |
| 营收同比 | 3.1% | 4.8% |
| 净利润同比 | 2406.4% | 2.9% |
| 每股收益（稀释后） | $0.16 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DOCRPRX
| Q4 25 | $719.4M | $622.0M | ||
| Q3 25 | $705.9M | $609.3M | ||
| Q2 25 | $694.3M | $578.7M | ||
| Q1 25 | $702.9M | $568.2M | ||
| Q4 24 | $698.0M | $593.6M | ||
| Q3 24 | $700.4M | $564.7M | ||
| Q2 24 | $695.5M | $537.3M | ||
| Q1 24 | $606.6M | $568.0M |
净利润DOCRPRX
| Q4 25 | $114.0M | $214.2M | ||
| Q3 25 | $-117.1M | $288.2M | ||
| Q2 25 | $31.7M | $30.2M | ||
| Q1 25 | $42.8M | $238.3M | ||
| Q4 24 | $4.5M | $208.2M | ||
| Q3 24 | $85.9M | $544.0M | ||
| Q2 24 | $146.0M | $102.0M | ||
| Q1 24 | $6.7M | $4.8M |
毛利率DOCRPRX
| Q4 25 | — | — | ||
| Q3 25 | 58.6% | — | ||
| Q2 25 | 60.2% | — | ||
| Q1 25 | 61.1% | — | ||
| Q4 24 | 60.3% | — | ||
| Q3 24 | 60.0% | — | ||
| Q2 24 | 60.6% | — | ||
| Q1 24 | 59.8% | — |
营业利润率DOCRPRX
| Q4 25 | 17.4% | 62.4% | ||
| Q3 25 | 9.2% | 70.1% | ||
| Q2 25 | 5.7% | 36.3% | ||
| Q1 25 | 7.7% | 94.0% | ||
| Q4 24 | -2.2% | 60.9% | ||
| Q3 24 | 14.1% | — | ||
| Q2 24 | 22.3% | 50.2% | ||
| Q1 24 | 3.7% | -13.0% |
净利率DOCRPRX
| Q4 25 | 73.2% | 34.4% | ||
| Q3 25 | -16.6% | 47.3% | ||
| Q2 25 | 4.6% | 5.2% | ||
| Q1 25 | 6.1% | 41.9% | ||
| Q4 24 | 0.7% | 35.1% | ||
| Q3 24 | 12.3% | 96.3% | ||
| Q2 24 | 21.0% | 19.0% | ||
| Q1 24 | 1.1% | 0.8% |
每股收益（稀释后）DOCRPRX
| Q4 25 | $0.16 | $0.49 | ||
| Q3 25 | $-0.17 | $0.67 | ||
| Q2 25 | $0.05 | $0.07 | ||
| Q1 25 | $0.06 | $0.55 | ||
| Q4 24 | $0.02 | $0.46 | ||
| Q3 24 | $0.12 | $1.21 | ||
| Q2 24 | $0.21 | $0.23 | ||
| Q1 24 | $0.01 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $467.5M | $618.7M |
| 总债务越低越好 | $9.8B | $9.0B |
| 股东权益账面价值 | $7.5B | $9.7B |
| 总资产 | $20.3B | $19.6B |
| 负债/权益比越低杠杆越低 | 1.31× | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资DOCRPRX
| Q4 25 | $467.5M | $618.7M | ||
| Q3 25 | $91.0M | $938.9M | ||
| Q2 25 | $89.4M | $631.9M | ||
| Q1 25 | $70.6M | $1.1B | ||
| Q4 24 | $119.8M | $929.0M | ||
| Q3 24 | $180.4M | $950.1M | ||
| Q2 24 | $106.9M | $1.8B | ||
| Q1 24 | $101.8M | $843.0M |
总债务DOCRPRX
| Q4 25 | $9.8B | $9.0B | ||
| Q3 25 | $9.1B | $8.9B | ||
| Q2 25 | $9.0B | $8.0B | ||
| Q1 25 | $8.9B | $7.6B | ||
| Q4 24 | $8.7B | $7.6B | ||
| Q3 24 | $8.6B | $7.6B | ||
| Q2 24 | $8.6B | $7.6B | ||
| Q1 24 | $8.8B | $6.1B |
股东权益DOCRPRX
| Q4 25 | $7.5B | $9.7B | ||
| Q3 25 | $7.6B | $9.6B | ||
| Q2 25 | $7.9B | $9.5B | ||
| Q1 25 | $8.2B | $9.8B | ||
| Q4 24 | $8.4B | $10.3B | ||
| Q3 24 | $8.6B | $10.3B | ||
| Q2 24 | $8.8B | $9.8B | ||
| Q1 24 | $8.9B | $9.9B |
总资产DOCRPRX
| Q4 25 | $20.3B | $19.6B | ||
| Q3 25 | $19.6B | $19.3B | ||
| Q2 25 | $19.8B | $18.3B | ||
| Q1 25 | $19.8B | $17.6B | ||
| Q4 24 | $19.9B | $18.2B | ||
| Q3 24 | $20.0B | $18.0B | ||
| Q2 24 | $20.2B | $17.7B | ||
| Q1 24 | $20.5B | $16.1B |
负债/权益比DOCRPRX
| Q4 25 | 1.31× | 0.92× | ||
| Q3 25 | 1.20× | 0.93× | ||
| Q2 25 | 1.14× | 0.84× | ||
| Q1 25 | 1.08× | 0.78× | ||
| Q4 24 | 1.04× | 0.74× | ||
| Q3 24 | 1.00× | 0.74× | ||
| Q2 24 | 0.98× | 0.78× | ||
| Q1 24 | 0.99× | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.3B | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $357.0M | — |
| 自由现金流率自由现金流/营收 | 49.6% | — |
| 资本支出强度资本支出/营收 | 124.4% | — |
| 现金转化率经营现金流/净利润 | 10.99× | 3.86× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流DOCRPRX
| Q4 25 | $1.3B | $827.1M | ||
| Q3 25 | $315.0M | $702.6M | ||
| Q2 25 | $363.5M | $364.0M | ||
| Q1 25 | $279.4M | $596.1M | ||
| Q4 24 | $1.1B | $742.5M | ||
| Q3 24 | $318.2M | $703.6M | ||
| Q2 24 | $316.2M | $658.2M | ||
| Q1 24 | $152.6M | $664.6M |
自由现金流DOCRPRX
| Q4 25 | $357.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $333.7M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
自由现金流率DOCRPRX
| Q4 25 | 49.6% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 47.8% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
资本支出强度DOCRPRX
| Q4 25 | 124.4% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 105.6% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金转化率DOCRPRX
| Q4 25 | 10.99× | 3.86× | ||
| Q3 25 | — | 2.44× | ||
| Q2 25 | 11.48× | 12.06× | ||
| Q1 25 | 6.52× | 2.50× | ||
| Q4 24 | 235.43× | 3.57× | ||
| Q3 24 | 3.71× | 1.29× | ||
| Q2 24 | 2.17× | 6.45× | ||
| Q1 24 | 22.85× | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DOC
暂无分部数据
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
